Laboratorios Farmaceuticos Rovi, S.A. Stock

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 11:35:14 2024-06-07 am EDT 5-day change 1st Jan Change
90 EUR -0.50% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. +2.56% +49.50%
Sales 2024 * 819M 885M Sales 2025 * 907M 980M Capitalization 4.66B 5.04B
Net income 2024 * 176M 190M Net income 2025 * 212M 229M EV / Sales 2024 * 5.65 x
Net cash position 2024 * 38.22M 41.28M Net cash position 2025 * 147M 159M EV / Sales 2025 * 4.98 x
P/E ratio 2024 *
27.2 x
P/E ratio 2025 *
22.6 x
Employees 1,925
Yield 2024 *
1.25%
Yield 2025 *
1.48%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 day-0.50%
1 week+2.56%
Current month+2.56%
1 month+8.70%
3 months+14.07%
6 months+58.31%
Current year+49.50%
More quotes
1 week
84.65
Extreme 84.65
90.75
1 month
79.85
Extreme 79.85
94.80
Current year
60.35
Extreme 60.35
94.80
1 year
37.96
Extreme 37.96
94.80
3 years
35.20
Extreme 35.2
94.80
5 years
19.80
Extreme 19.8
94.80
10 years
7.90
Extreme 7.9
94.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - 93-12-31
Director of Finance/CFO - 99-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 94-12-31
Director of Finance/CFO - 99-12-31
Chief Executive Officer - 93-12-31
More insiders
Date Price Change Volume
24-06-07 90 -0.50% 28,846
24-06-06 90.45 +0.50% 40,349
24-06-05 90 +0.50% 43,589
24-06-04 89.55 +0.90% 59,860
24-06-03 88.75 +1.14% 51,002

Delayed Quote BME, June 07, 2024 at 11:35 am EDT

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
90 EUR
Average target price
89.44 EUR
Spread / Average Target
-0.62%
Consensus

Quarterly revenue - Rate of surprise